0001694665-23-000134.txt : 20230809 0001694665-23-000134.hdr.sgml : 20230809 20230809204239 ACCESSION NUMBER: 0001694665-23-000134 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230807 FILED AS OF DATE: 20230809 DATE AS OF CHANGE: 20230809 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McHale Duncan CENTRAL INDEX KEY: 0001738896 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38473 FILM NUMBER: 231156895 MAIL ADDRESS: STREET 1: C/O EVELO BIOSCIENCES, INC. STREET 2: 620 MEMORIAL DRIVE, SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Evelo Biosciences, Inc. CENTRAL INDEX KEY: 0001694665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 465594527 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 620 MEMORIAL DRIVE SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-577-0300 MAIL ADDRESS: STREET 1: 620 MEMORIAL DRIVE SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 wk-form4_1691628149.xml FORM 4 X0508 4 2023-08-07 0 0001694665 Evelo Biosciences, Inc. EVLO 0001738896 McHale Duncan C/O EVELO BIOSCIENCES, INC. 620 MEMORIAL DRIVE CAMBRIDGE MA 02139 0 1 0 0 Chief Medical Officer 1 Common Stock 2023-08-07 4 M 0 6500 A 11375 D Common Stock 2023-08-08 4 S 0 3434 9.51 D 7941 D Restricted Stock Units 2023-08-07 4 M 0 6500 0 D Common Stock 6500 13000 D Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices within the range of $9.08 to $9.55, inclusive. The reporting person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. The RSUs vest in four (4) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the first anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. These RSUs have no expiration date. On June 29, 2023, the Issuer effected a 1-for-20 reverse stock split. The share counts herein have been adjusted to reflect the reverse stock split. /s/ Marella Thorell, Attorney-in-Fact for Duncan McHale 2023-08-09